8-K: Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth, Raises Full-Year Revenue Guidance

Alnylam Pharmaceuticals announced robust second-quarter 2025 financial results, driven by significant growth in AMVUTTRA sales, leading to an upward revision of its full-year revenue guidance.

Summary

• Total Net Product Revenues for Q2 2025 reached $672 million, marking a 64% increase compared to Q2 2024.
• Total TTR Revenues, primarily from AMVUTTRA and ONPATTRO, were $544 million, representing 77% growth over Q2 2024.
• Approximately 1,400 ATTR-CM patients were on AMVUTTRA as of June 30, 2025.
• AMVUTTRA received regulatory approvals for the treatment of ATTR-CM in the European Union, Brazil, the United Kingdom, and Japan.
• The TRITON-CM Phase 3 trial of nucresiran in patients with wild-type or hereditary ATTR-CM was initiated.
• Full-year 2025 guidance for Total TTR Net Product Revenues was raised to $2,175 million to $2,275 million.
• Full-year 2025 guidance for Total Net Product Revenues was raised to $2,650 million to $2,800 million, a $575 million or 27% increase at the midpoint.
• GAAP Net loss per common share was $(0.51) for Q2 2025, compared to $(0.13) for Q2 2024.
• Non-GAAP Net income per common share was $0.34 for Q2 2025, compared to $0.58 for Q2 2024.
• Cash, cash equivalents, and marketable securities stood at $2.86 billion as of June 30, 2025, an increase from $2.63 billion as of March 31, 2025.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, particularly from its key product AMVUTTRA, and significantly raised its full-year revenue guidance, indicating strong market uptake and confidence. While GAAP net loss increased and non-GAAP net income decreased, this is largely attributable to increased R&D and SG&A investments for pipeline advancement and product launches, which are positive long-term indicators. The robust cash position and active pipeline development further support a positive outlook.

Positives

• Achieved Q2 2025 Total Net Product Revenues of $672 million, a 64% growth compared with Q2 2024.
• Generated Total TTR Revenues of $544 million, representing 77% growth compared with Q2 2024, driven primarily by AMVUTTRA.
• Approximately 1,400 ATTR-CM patients were on AMVUTTRA as of June 30, 2025, indicating strong initial uptake.
• Obtained regulatory approvals for AMVUTTRA for ATTR-CM in the European Union, Brazil, the United Kingdom, and Japan, expanding market access.
• Presented additional 42-month data from the HELIOS-B Phase 3 trial of vutrisiran, reinforcing its effect on all-cause mortality (36% reduction) and CV mortality (33% reduction).
• Initiated the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM patients and received Fast Track Designation from the FDA for nucresiran.
• Raised 2025 guidance for Total TTR Franchise Net Revenues and Total Net Product Revenues, reflecting increased confidence in future performance.
• GIVLAARI and OXLUMO achieved global net product revenue growth of 30% and 15% respectively, contributing to overall rare disease portfolio growth.
• Presented positive Phase 1 data for mivelsiran in Alzheimer's disease, showing robust, durable, dose-dependent reductions of soluble amyloid precursor protein beta (sAPP) in CSF.
• Initiated a Phase 1 clinical trial for ALN-4324, an insulin sensitizer for the treatment of type 2 diabetes.
• Partner Agios Pharmaceuticals received IND clearance for AG-236 (ALN-TMP) and initiated a Phase 1 healthy volunteer study for polycythemia vera.
• Cash, cash equivalents, and marketable securities increased to $2.86 billion as of June 30, 2025, demonstrating strong financial liquidity.

Negatives

• GAAP Net loss per common share increased to $(0.51) in Q2 2025 from $(0.13) in Q2 2024.
• Non-GAAP Net income per common share decreased to $0.34 in Q2 2025 from $0.58 in Q2 2024.
• ONPATTRO net product revenues decreased by 32% in Q2 2025 compared to Q2 2024, primarily due to patient switches to AMVUTTRA.
• Net revenues from collaborations decreased by 73% in Q2 2025, mainly due to a non-recurring $185.0 million revenue recognition from Regeneron Pharmaceuticals in Q2 2024.
• Cost of goods sold increased by 111% in Q2 2025 compared to Q2 2024, and as a percentage of net product revenues, increased from 16.4% to 21.1%.
• GAAP and non-GAAP Research and development expenses increased by 10% and 11% respectively, due to increased clinical trial startup activities.
• GAAP and non-GAAP Selling, general and administrative expenses increased by 30% and 26% respectively, driven by higher employee compensation and marketing investment for AMVUTTRA launch.
• GAAP (Loss) income from operations shifted to a loss of $(16,199) thousand in Q2 2025 from an income of $48,614 thousand in Q2 2024.
• Non-GAAP Income from operations decreased by 31% in Q2 2025.
• Provision for income taxes increased to $30.9 million in Q2 2025.

Risks

• Ability to successfully execute on the Alnylam P5x25 strategy.
• Ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of product candidates.
• Uncertainty of pre-clinical and clinical results for product candidates, including zilebesiran, nucresiran, and mivelsiran.
• Actions or advice of regulatory agencies and ability to obtain and maintain regulatory approval for product candidates, as well as favorable pricing and reimbursement.
• Challenges in successfully launching, marketing, and selling approved products globally.
• Potential for delays, interruptions, or failures in the manufacture and supply of product candidates or marketed products.
• Challenges in obtaining, maintaining, and protecting intellectual property.
• Ability to manage growth and operating expenses through disciplined investment and achieve a self-sustainable financial profile without the need for future equity financing.
• Ability to maintain strategic business collaborations.
• Dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron.
• Outcome of litigation.
• Risk of future government investigations.
• Unexpected expenditures.

Future Outlook

Alnylam raised its full-year 2025 guidance for Total TTR net product revenues to $2,175 million $2,275 million and Total net product revenues to $2,650 million $2,800 million, representing a 27% increase at the midpoint. The company expects to initiate two more Phase 3 trials in the second half of 2025: TRITON-PN for nucresiran in hATTR-PN and the cardiovascular outcomes trial of zilebesiran in hypertension, along with a Phase 2 trial of mivelsiran in Alzheimer's disease.

Management Comments

• "Our results during the second quarter highlight Alnylam's unique ability to quickly deliver and enable commercial access to innovative medicines for patients, while continuing to advance our high-value pipeline of investigational RNAi therapeutics."
• "Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year."
• "While still early in the launch, we are very encouraged by the initial pace of uptake, evidence of the clear need for a novel mechanism in ATTR-CM and the effectiveness of our broad patient access efforts."
• "Based on the strong progress during the first half of 2025 and our confidence in the overall business for the rest of the year, we are raising our total net product revenue guidance range by 27% at the midpoint, driven by an upward revision to our TTR franchise revenue guidance."
• "The remarkable pace and depth of our progress positions us to deliver on our Alnylam P5x25 goals as we advance toward sustainable profitability and solidify ourselves as a top-tier biotech company delivering transformational innovation to patients."

Industry Context

Alnylam is a leader in RNAi therapeutics, a rapidly advancing field in biology and drug development. The strong performance of AMVUTTRA, particularly in ATTR-CM, demonstrates the growing acceptance and demand for novel RNAi-based treatments for rare and prevalent diseases. The company's robust pipeline, with multiple late-stage candidates, positions it to maintain its leadership and potentially expand into larger therapeutic areas like hypertension and Alzheimer's, which could significantly broaden its market reach beyond rare diseases. The shift from ONPATTRO to AMVUTTRA for some patients highlights the company's ability to innovate within its own portfolio and offer improved treatment options.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct comparison.
• Alnylam's RNAi platform is considered a leading technology in the biotech industry, having pioneered the development of this new class of medicines.
• The 64% year-over-year growth in total net product revenues is a strong indicator of market penetration and demand, especially for a specialized therapeutic area like ATTR-CM, and would generally be considered above average for established pharmaceutical companies.
• The successful global approvals for AMVUTTRA in ATTR-CM (EU, Brazil, UK, Japan) demonstrate strong regulatory execution, comparable to top-tier pharmaceutical companies expanding market access for new therapies.
• The initiation of multiple Phase 3 trials (nucresiran, zilebesiran) and a Phase 2 trial (mivelsiran) indicates a robust and active R&D pipeline, consistent with a leading biotech company focused on long-term growth and innovation.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, raised guidance, and pipeline advancements, potentially leading to increased share value.
• Patients: Increased access to innovative RNAi therapeutics like AMVUTTRA due to global approvals and patient access efforts, and potential for new treatments from the pipeline.
• Employees: Continued growth and pipeline expansion suggest job stability and potential for new opportunities.
• Partners (Roche, Regeneron, Novartis, Sanofi, Agios): Continued collaboration and progress on partnered programs.
• Creditors: Strong cash position and increased revenues improve financial stability.

Next Steps

• Present results from the KARDIA-3 Phase 2 trial of zilebesiran in hypertension during a Hot Line Session at the European Society of Cardiology (ESC) Congress in Madrid, Spain on August 30, 2025.
• Initiate a Phase 3 cardiovascular outcomes trial of zilebesiran, in collaboration with Roche, in the second half of 2025.
• Initiate the TRITON-PN Phase 3 trial of nucresiran in hATTR-PN in the second half of 2025.
• Initiate a Phase 2 trial of mivelsiran in Alzheimer's disease in the second half of 2025.
• Regeneron Pharmaceuticals plans to share results from the Phase 3 trial of cemdisiran tested as a monotherapy and in combination with pozelimab in patients with myasthenia gravis in the second half of 2025.

Key Dates

Recommendation

The company demonstrated exceptional revenue growth driven by its flagship product AMVUTTRA, significantly exceeding prior expectations and leading to a substantial upward revision of full-year guidance. This indicates strong market adoption and a robust commercial strategy. While GAAP net loss increased, it's primarily due to strategic investments in R&D and SG&A to fuel future growth and product launches, which is a healthy sign for a biotech company. The deep and advancing pipeline, including multiple late-stage programs and new indications, provides significant future growth potential and diversification. The strong cash position further supports these initiatives. The overall performance and outlook suggest a company executing well on its strategy with considerable upside potential.

Keywords

RNAi therapeutics, Alnylam, AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, ATTR-CM, hATTR-PN, nucresiran, zilebesiran, mivelsiran, Alzheimer's disease, hypertension, polycythemia vera, rare diseases, pharmaceutical, biotechnology, drug development, clinical trials, financial results, earnings, revenue guidance